David A. Siegel Mereo Biopharma Group PLC Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 29,300 shares of MREO stock, worth $65,925. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,300Holding current value
$65,925% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding MREO
# of Institutions
100Shares Held
111MCall Options Held
1MPut Options Held
668K-
Janus Henderson Group PLC London, X022.7MShares$51.2 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$34.4 Million0.99% of portfolio
-
Mangrove Partners New York, NY8.64MShares$19.4 Million3.05% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.82MShares$17.6 Million1.11% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$15.1 Million0.38% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $281M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...